Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NMDA Antagonist, CP-101, 606 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| NMDA Antagonist, CP-101,606 (traxoprodil) | DRUG | - |
Inclusion Criteria: * Primary DSM-IV diagnosis of MDD Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, bu...
NMDA Antagonist, CP-101,606 is an investigational small molecule being studied for the treatment of Major Depressive Disorder (MDD). It is in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is intended for patients with this psychiatric condition.
NMDA Antagonist, CP-101,606 targets the N-methyl-D-aspartate (NMDA) receptor, as indicated by its name. By antagonizing this receptor, the drug is being investigated for its potential antidepressant effects in patients with Major Depressive Disorder.
NMDA Antagonist, CP-101,606 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical research on this investigational drug for the treatment of Major Depressive Disorder.
NMDA Antagonist, CP-101,606 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied for its potential use in treating Major Depressive Disorder.
NMDA Antagonist, CP-101,606 has one completed Phase 2 clinical trial, identified as NCT00163059. This study, titled 'The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD,' enrolled 30 participants in the United States and was not blinded or controlled.